Context Therapeutics (NASDAQ:CNTX) Shares Up 2.1% – Time to Buy?

Context Therapeutics Inc. (NASDAQ:CNTX)’s stock price rose 2.1% during trading on Monday . The company traded as high as $0.83 and last traded at $0.83. Approximately 81,173 shares changed hands during trading, a decline of 62% from the average daily volume of 216,034 shares. The stock had previously closed at $0.81.

Analyst Ratings Changes

CNTX has been the subject of a number of analyst reports. Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Wednesday, January 15th. Finally, JMP Securities initiated coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Context Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $6.33.

Context Therapeutics Price Performance

The stock has a 50 day moving average price of $0.98 and a 200-day moving average price of $1.65. The stock has a market capitalization of $62.36 million, a price-to-earnings ratio of -0.91 and a beta of 2.06.

Institutional Investors Weigh In On Context Therapeutics

A number of large investors have recently modified their holdings of the business. State Street Corp boosted its position in Context Therapeutics by 21.5% during the third quarter. State Street Corp now owns 111,907 shares of the company’s stock worth $219,000 after acquiring an additional 19,800 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Context Therapeutics during the 3rd quarter worth approximately $89,000. Franklin Resources Inc. purchased a new stake in shares of Context Therapeutics in the third quarter valued at approximately $3,689,000. Clear Harbor Asset Management LLC increased its holdings in shares of Context Therapeutics by 60.6% in the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock valued at $61,000 after purchasing an additional 21,804 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Context Therapeutics by 9.2% during the fourth quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock worth $661,000 after buying an additional 52,830 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.